WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for PhaseBio Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-06 3:02 pm Sale |
2022-12-30 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 0 0.000% |
-2,869,650 (Position Closed) |
Filing |
| 2022-02-04 09:29 am Purchase |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 2,869,650 5.970% |
944,570 (+49.07%) |
Filing |
| 2021-11-10 08:51 am Sale |
2021-10-29 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 1,925,080 4.010% |
-4,089,809 (-67.99%) |
Filing |
| 2021-08-10 07:57 am Purchase |
2021-07-30 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 6,014,889 12.540% |
4,447,233 (+283.69%) |
Filing |
| 2021-01-11 09:10 am Sale |
2020-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 1,567,656 5.340% |
-2,324,600 (-59.72%) |
Filing |